Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Predicting high-risk endometrioid carcinomas using proteins.

Du D, Ma W, Yates MS, Chen T, Lu KH, Lu Y, Weinstein JN, Broaddus RR, Mills GB, Liu Y.

Oncotarget. 2018 Apr 13;9(28):19704-19715. doi: 10.18632/oncotarget.24803. eCollection 2018 Apr 13.

2.

Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese women at increased risk for endometrial cancer.

Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen DR, Soletsky B, Milbourne A, Levy E, Fellman BM, Urbauer DL, Yuan Y, Broaddus RR, Basen-Engquist K, Lu K.

Cancer Prev Res (Phila). 2018 May 1. pii: canprevres.0398.2017. doi: 10.1158/1940-6207.CAPR-17-0398. [Epub ahead of print]

PMID:
29716897
3.

Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.

Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY, Lu KH.

Int J Gynecol Cancer. 2017 Jun;27(5):854-862. doi: 10.1097/IGC.0000000000000960.

PMID:
28498246
4.

Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.

Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS.

Clin Cancer Res. 2017 Aug 1;23(15):4473-4481. doi: 10.1158/1078-0432.CCR-16-2655. Epub 2017 Mar 6.

PMID:
28264871
5.

Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.

Iglesias DA, Zhang Q, Celestino J, Sun CC, Yates MS, Schmandt RE, Lu KH.

Oncology. 2017;92(2):109-114. doi: 10.1159/000450615. Epub 2016 Dec 9.

6.

Bringing Cancer Prevention Research Competencies to the Classroom.

Yates MS, Chang S, Lee HY, Faupel-Badger J, Cameron C.

J Cancer Educ. 2018 Feb;33(1):109-115. doi: 10.1007/s13187-016-1063-9.

PMID:
27325275
7.

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL.

J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26.

8.

Salpingectomy as a means to reduce ovarian cancer risk.

Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH.

Cancer Prev Res (Phila). 2015 May;8(5):342-8. doi: 10.1158/1940-6207.CAPR-14-0293. Epub 2015 Jan 13. Review.

9.

CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.

Zhang Q, Schmandt R, Celestino J, McCampbell A, Yates MS, Urbauer DL, Broaddus RR, Loose DS, Shipley GL, Lu KH.

Gynecol Oncol. 2014 Apr;133(1):83-9. doi: 10.1016/j.ygyno.2013.12.006.

10.

Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.

Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, Lu KH.

Mol Cancer Ther. 2013 Dec;12(12):2847-56. doi: 10.1158/1535-7163.MCT-13-0439. Epub 2013 Sep 27.

11.

Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome.

Huang M, Djordjevic B, Yates MS, Urbauer D, Sun C, Burzawa J, Daniels M, Westin SN, Broaddus R, Lu K.

Cancer. 2013 Aug 15;119(16):3027-33. doi: 10.1002/cncr.28152. Epub 2013 Jun 12.

12.

Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome.

Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR.

Cancer Prev Res (Phila). 2013 Aug;6(8):774-81. doi: 10.1158/1940-6207.CAPR-13-0020. Epub 2013 May 2.

13.

Chemopreventive effects of metformin on obesity-associated endometrial proliferation.

Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH.

Am J Obstet Gynecol. 2013 Jul;209(1):24.e1-24.e12. doi: 10.1016/j.ajog.2013.03.008. Epub 2013 Mar 15.

14.

Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH.

Cancer Prev Res (Phila). 2011 Mar;4(3):463-70. doi: 10.1158/1940-6207.CAPR-10-0266. Epub 2011 Jan 28.

15.

The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention.

Lu KH, Yates MS, Mok SC.

Cancer Prev Res (Phila). 2009 Sep;2(9):773-5. doi: 10.1158/1940-6207.CAPR-09-0156. Epub 2009 Sep 8.

16.

Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.

Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M, Kensler TW.

Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44. doi: 10.1016/j.ejphar.2009.08.022. Epub 2009 Aug 19.

17.

The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.

Reddy NM, Suryanaraya V, Yates MS, Kleeberger SR, Hassoun PM, Yamamoto M, Liby KT, Sporn MB, Kensler TW, Reddy SP.

Am J Respir Crit Care Med. 2009 Nov 1;180(9):867-74. doi: 10.1164/rccm.200905-0670OC. Epub 2009 Aug 13.

18.

Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.

Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW.

Carcinogenesis. 2009 Jun;30(6):1024-31. doi: 10.1093/carcin/bgp100. Epub 2009 Apr 21.

19.

Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.

Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, Biswal S.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):250-5. doi: 10.1073/pnas.0804333106. Epub 2008 Dec 22.

20.

A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.

Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, Groopman JD, Kensler TW, Sporn MB.

Cancer Res. 2008 Aug 15;68(16):6727-33. doi: 10.1158/0008-5472.CAN-08-1123.

21.

Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice.

Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, Kensler TW.

Toxicol Sci. 2008 Jul;104(1):218-27. doi: 10.1093/toxsci/kfn079. Epub 2008 Apr 15.

22.

Keap1 eye on the target: chemoprevention of liver cancer.

Yates MS, Kensler TW.

Acta Pharmacol Sin. 2007 Sep;28(9):1331-42. Review.

23.

Chemopreventive promise of targeting the Nrf2 pathway.

Yates MS, Kensler TW.

Drug News Perspect. 2007 Mar;20(2):109-17. Review.

PMID:
17440634
24.

Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.

Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW.

Mol Cancer Ther. 2007 Jan;6(1):154-62.

25.

Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler TW.

Cancer Res. 2006 Feb 15;66(4):2488-94.

26.

Chronic hypoxia up-regulates expression of adenosine A1 receptors in DDT1-MF2 cells.

Hammond LC, Bonnet C, Kemp PJ, Yates MS, Bowmer CJ.

Biochem Pharmacol. 2004 Feb 1;67(3):421-6.

PMID:
15037194
27.

Alternative learning environments: what do they contribute to professional development of medical students?

Yates MS, Drewery S, Murdoch-Eaton DG.

Med Teach. 2002 Nov;24(6):609-15.

PMID:
12623454
28.

Immunolocalisation of adenosine A(1) receptors in the rat kidney.

Smith JA, Sivaprasadarao A, Munsey TS, Bowmer CJ, Yates MS.

Biochem Pharmacol. 2001 Jan 15;61(2):237-44.

PMID:
11163338
29.

Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney.

Oldroyd SD, Fang L, Haylor JL, Yates MS, El Nahas AM, Morcos SK.

Clin Sci (Lond). 2000 Mar;98(3):303-11.

PMID:
10677389
30.

Differential expression of renal adenosine A(1) receptors induced by acute renal failure.

Smith JA, Whitaker EM, Bowmer CJ, Yates MS.

Biochem Pharmacol. 2000 Mar 15;59(6):727-32.

PMID:
10677590
31.

Regulation of renal adenosine A(1) receptors: effect of dietary sodium chloride.

Smith JA, Whitaker EM, Yaktubay N, Morton MJ, Bowmer CJ, Yates MS.

Eur J Pharmacol. 1999 Nov 12;384(1):71-9.

PMID:
10611422
32.
33.

The haemodynamic effects of iodinated water soluble radiographic contrast media: a review.

Morcos SK, Dawson P, Pearson JD, Jeremy JY, Davenport AP, Yates MS, Tirone P, Cipolla P, de Haƫn C, Muschick P, Krause W, Refsum H, Emery CJ, Liss P, Nygren A, Haylor J, Pugh ND, Karlsson JO.

Eur J Radiol. 1998 Nov;29(1):31-46. Review.

PMID:
9934557
34.

Adenosine receptor mRNA levels during postnatal renal maturation in the rat.

Morton MJ, Sivaprasadarao A, Bowmer CJ, Yates MS.

J Pharm Pharmacol. 1998 Jun;50(6):649-54.

PMID:
9680076
36.

K(+)-induced dilation of a small renal artery: no role for inward rectifier K+ channels.

Prior HM, Webster N, Quinn K, Beech DJ, Yates MS.

Cardiovasc Res. 1998 Mar;37(3):780-90.

PMID:
9659463
37.

Renal adenosine A1 receptor binding characteristics and mRNA levels during the development of acute renal failure in the rat.

Gould J, Morton MJ, Sivaprasadarao A, Bowmer CJ, Yates MS.

Br J Pharmacol. 1997 Mar;120(5):947-53.

38.

Amelioration of cisplatin nephrotoxicity with glycine: dose dependency in rats.

Li Q, Bowmer CJ, Yates MS.

J Pharm Pharmacol. 1995 Mar;47(3):223-6.

PMID:
7602485
39.

Renal haemodynamic responses to adenosine in acute renal failure.

Gould J, Bowmer CJ, Yates MS.

Nephron. 1995;71(2):184-9.

PMID:
8569952
40.

Effect of arginine on cisplatin-induced acute renal failure in the rat.

Li Q, Bowmer CJ, Yates MS.

Biochem Pharmacol. 1994 Jun 15;47(12):2298-301.

PMID:
8031325
41.

Diuretic effect of NG-nitro-L-arginine methyl ester in the rat.

Li Q, Bowmer CJ, Yates MS.

J Pharm Pharmacol. 1994 Jun;46(6):510-2.

PMID:
7932050
42.
44.
45.

Cardiac function in rats with acute renal failure.

Robinson SC, Bowmer CJ, Yates MS.

J Pharm Pharmacol. 1992 Dec;44(12):1007-14.

PMID:
1281876
46.

A comparison of drug binding sites on mammalian albumins.

Panjehshahin MR, Yates MS, Bowmer CJ.

Biochem Pharmacol. 1992 Sep 1;44(5):873-9.

PMID:
1382424
47.

Further characterization of the protective effect of 8-cyclopentyl-1,3-dipropylxanthine on glycerol-induced acute renal failure in the rat.

Panjehshahin MR, Munsey TS, Collis MG, Bowmer CJ, Yates MS.

J Pharm Pharmacol. 1992 Feb;44(2):109-13.

PMID:
1352809
48.

Amelioration of cisplatin-induced acute renal failure with 8-cyclopentyl-1,3-dipropylxanthine.

Knight RJ, Collis MG, Yates MS, Bowmer CJ.

Br J Pharmacol. 1991 Dec;104(4):1062-8.

49.

The effect of 8-cyclopentyl-1,3-dipropylxanthine on the development of cyclosporin-induced acute renal failure.

Panjehshahin MR, Chahil RS, Collis MG, Bowmer CJ, Yates MS.

J Pharm Pharmacol. 1991 Jul;43(7):525-8.

PMID:
1682472
50.

Supplemental Content

Loading ...
Support Center